Showing 7 posts of 7 posts found.


NHS to save £300 million by switching to Humira biosimilars

November 27, 2018
Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …


Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data

September 15, 2017
Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical

Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …


AbbVie’s Humira receives first European OK for skin condition

August 3, 2015
Sales and Marketing AbbVie, Hidradenitis suppurativa, Humira, adalimumab

The European Commission has approved AbbVie’s Humira as a treatment for moderate-to-severe hidradenitis suppurativa – a chronic condition affecting the …

Humira image

AbbVie’s Humira meets endpoint in eye disease study

May 6, 2015
Research and Development, Sales and Marketing AbbVie, FDA, Humira, Zydus Cadila, adalimumab, uveitis

In a Phase III trial AbbVie’s anti-inflammatory medicine Humira has been shown to significantly lower the risk of uncontrolled uveitis …

Abbbie image

AbbVie buys Pharmacyclics in $21 billion deal

March 5, 2015
Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica

AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …

Amgen image

Late-stage successes for Amgen and Roche

February 5, 2015
Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab

Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …

EMA image

EMA responds to redaction concerns

November 14, 2014
Sales and Marketing AbbVie, EMA, Goldacre, Humira, Rasi, adalimumab, redactions, transparency

The EMA has published a response to European Ombudsman Emily O’Reilly’s questions about some of its trial data redactions. O’Reilly’s …

Latest content